Figure 1: Changes in gross morphological scores amongst the four experimental treatment groups
While much of the research remains in preclinical stages, early findings are promising
If you have a family history of medullary thyroid cancer, multiple endocrine neoplasias, or acute pancreatitis, it is advisable to avoid using GLP-1 drugs
Right now, the focus is largely on their role in managing diabetes and obesity, but the research is really starting to show some interesting possibilities for mood disorders
Patients with pernicious anemia or others who cannot absorb B from food typically need lifelong B therapy, often on a monthly injection schedule
The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
.png)
